The Coefficient of Variation of Red Blood Cell Distribution Width Combined with Cancer Antigen 125 Predicts Postoperative Overall Survival in Endometrial Cancer

Figures & data

Table 1 The Characteristics of Clinical Indicators in EC with Early and Advanced Stage

Parameter	I–II(n=446)	III–IV(n=51)	P
Age at surgery, median (Range), years	54(49–59)	53(49–61)	0.789
BMI, median (Range), kg/m2	24.12(22.21–26.56)	24.45(22.36–26.16)	0.795
WBC, median (Range), 10^9/L	6.13(5.01–7.16)	6.21(5.28–7.41)	0.286
NE, median (Range), 10^9/L	3.38(2.71–4.33)	3.71(2.84–4.92)	0.130
RBC, median (Range), 10^9/L	4.27(4.00–4.60)	4.16(3.94–4.51)	0.210
HB, median (Range), g/L	126.00(116.25–134.00)	121.50(111.00–133.25)	0.130
MCV, median (Range), fL	87.6(83.3–90.4)	85.0(81.5–89.4)	0.034
MCH, median (Range), pg	29.6(28.0–30.8)	28.7(26.8–29.9)	0.010
MCHC, median (Range), g/L	338(329–344)	334(327–342)	0.167
RDW-CV, median (Range), %	12.5(12.1–13.2)	13.2(12.65–15.55)	0.001
RDW-SD, median (Range), fL	40.3(38.8–42.5)	41.2(38.93–43.68)	0.185
CA125, median (Range), U/mL	18(11.60–28.58)	38.85(19.05–122.95)	<0.001
CA199, median (Range), U/mL	12.96(6.99–28.63)	23.63(11.52–68.84)	<0.001
CA153, median (Range), U/mL	8.8(6.7–12.7)	13.25(8.83–21.58)	<0.001
AFP, median (Range), ng/mL	2.46(1.80–3.36)	2.27(1.77–3.28)	0.467
CEA, median (Range), ug/L	1.71(1.17–2.56)	1.75(1.19–2.40)	0.097
Menopause status, n(%)
Premenopausal	223	23	0.507
Postmenopausal	223	28
History of diabetes, n(%)
Yes	354	39	0.629
No	92	12
History of hypertension, n(%)
Yes	267	36	0.137
No	169	15

Note: P<0.05 suggests significantly different.

Abbreviations: BMI, body mass index; WBC, white blood cell; NE, neutrophil; RBC, red blood cell; HB, hemoglobin; MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; MCHC, mean corpuscular hemoglobin concentration; RDW-CV, The coefficient of variation of red blood cell distribution; RDW-SD, standard deviation of red blood cell distribution; CA125, cancer antigen 125; CA199, cancer antigen 199; CA153, cancer antigen 153; AFP, alpha fetal protein; CEA, A carcinoma embryonic antigen.

Table 2 Univariate and Multivariate Logistic Regression Analyses for Stage

Parameter		Univariable	P1	Multivariable	P2
		OR (95% CI)		OR (95% CI)
MCV	≤85.05^R	0.406(0.226–0.769)	0.003	0.609(0.192–1.938)	0.609
	>85.05
MCH	≤29.45^R	0.414(0.225–0.764)	0.005	1.174(0.364–3.788)	0.789
	>29.45
RDW-CV	≤12.45^R	5.421(2.059–14.277)	0.001	4.635(1.437–14.951)	0.010
	>12.45
CA125	≤28.85^R	5.085(2.755–9.383)	<0.001	3.784(1.610–8.894)	0.002
	>28.85
CA199	≤18.88^R	3.136(1.632–6.025)	0.001	2.271(0.965–5.342)	0.060
	>18.88
CA153	≤9.45^R	3.508(1.811–6.794)	<0.001	2.127(0.893–5.062)	0.088
	>9.45

Note: P<0.05 suggests significantly different.

Abbreviations: MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; RDW-CV, the coefficient of variation of red blood cell distribution; CA125, cancer antigen 125; CA199, cancer antigen 199; CA153, cancer antigen 153; R, references group.

Figure 1 ROC curves of MCV, MCH, RDW-CV, CA125, CA199, CA153. P<0.05 suggests significantly different.

Table 3 Associations of RDW+CA125 with Clinical Characteristics

Parameters		RDWCV+CA125, n			P
		0	1	2
Age(years)	≤55	60	107	34	0.735
	˃55	45	67	25
BMI (kg/m^2)	≤25	55	106	35	0.326
	˃25	50	67	23
FIGO stage	I–II	100	156	38	<0.001
	III–IV	1	16	19
Menopause status	Premenopausal	43	88	34	0.139
	Postmenopausal	62	92	26
History of diabetes	Yes	20	41	11	0.657
	No	85	139	49
History of hypertension	Yes	42	72	20	0.629
	No	63	108	40

Note: P<0.05 suggests significantly different.

Abbreviations: BMI, body mass index; FIGO, International Federation of Gynecology and Obstetrics; RDW-CV, the coefficient of variation of red blood cell distribution; CA125, cancer antigen 125.

Table 4 Univariate and Multivariate Cox Proportional Hazards Regression Analyses for OS

Parameter		Univariable	P	Multivariable	P
		HR (95% CI)		HR (95% CI)
MCV	≤85.05^R	2.902(0.851–9.903)	0.086	–	–
	>85.05
MCH	≤29.45^R	1.379(0.564–3.375)	0.481	–	–
	>29.45
CA199	≤18.88^R	0.901(0.333–2.435)	0.836	–	–
	>18.88
CA153	≤9.45^R	1.194(0.485–2.937)	0.700	–	–
	>9.45
RDWCV+CA125	0^R	–	–	–	–
	1	3.256(0.722–14.689)	0.125	2.893(0.634–13.191)	0.170
	2	6.989(1.452–33.645)	0.015	5.488(1.081–27.855)	0.040
FIGO stage	I–II^R	3.335(1.212–9.177)	0.020	2.039(0.707–5.877)	0.187
	III–IV

Note: P<0.05 suggests significantly different.

Abbreviations: MCV, mean corpuscular volume; MCH, mean corpuscular hemoglobin; RDW-CV, the coefficient of variation of red blood cell distribution; CA125, cancer antigen 125; CA199, cancer antigen 199; CA153, cancer antigen 153; FIGO, International Federation of Gynecology and Obstetrics; R, references group.

Figure 2 (A) Kaplan–Meier curve for OS of EC patients stratified by RDW-CV+CA125. (B) Association of RDW-CV+CA125 with the OS of EC patients with FIGO stage III–IV. (C) Association of RDW-CV+CA125 with the OS of EC patients with FIGO stage I–II. P<0.05 suggests significantly different.